Express Pharma

MAY 17, 2023

Immuno-oncology (IO) agents have transformed the oncology landscape in the last decade, particularly immune checkpoint inhibitors (ICIs) in solid tumor settings and chimeric antigen receptor (CAR) T-cells in hematological malignancies, with patients who previously had very limited therapeutic options achieving long term remissions and even cure.

Immunity 91

Immunity Immunization Vaccines 91

European Pharmaceutical Review

OCTOBER 11, 2023

As part of newly acquired assets from live biotherapeutics products (LBP) manufacturer Federation Bio, Kanvas Biosciences now has two active microbiome-based clinical programmes. This acquisition allows us to manufacture and clinically investigate complex microbial consortia much faster than previously envisioned.

Immunity 82

Immunity Immunization 82

pharmaphorum

APRIL 12, 2021

Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for immuno-oncology. . Exscientia will lead the clinical development of the A2A drug, with Evotec retaining co-ownership rights.

Immunity 126

Immunity Immunization Compounding 126

Pharmaceutical Technology

MAY 25, 2023

Pyxis Oncology has made a definitive agreement to buy biopharmaceutical company Apexigen, in a deal valued at nearly $16m. Pyxis Oncology will issue 0.1725 shares of its common stock, with par value of $0.001 per share, for each Apexigen share.

Immunity 52

Immunity Immunization 52

pharmaphorum

JUNE 28, 2022

For Astellas, the alliance takes the spotlight off the current travails with its gene therapy programmes, with an FDA clinical hold imposed on another candidate – for Pompe disease – in the last few days. The post Astellas pumps $90m into Sutro immuno-oncology alliance appeared first on.

Immunity 104

Immunity Immunization 104

Pharmafile

JANUARY 5, 2023

Summary: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Published date: 05/01/2023. read more.

52

52

Pharmaceutical Technology

JULY 13, 2022

The initial agreement was signed in February 2020 for discovering, developing and marketing new immuno-oncology therapies based on Bicycle’s bicyclic peptide technology. The agreement is exclusive of the compounds in the oncology pipeline of Bicycle, including its immuno-oncology candidates.

Compounding 59

Compounding 59

Pharmaceutical Technology

DECEMBER 19, 2022

Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology. Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future.

105

105

pharmaphorum

JUNE 1, 2022

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5

98

98

Pharmaceutical Business Review

DECEMBER 8, 2023

With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express HHLA2, a tumor antigen that is strongly upregulated in several human cancers.

Immunity 59

Immunity Immunization 59

Big Molecule Watch

JUNE 22, 2023

and Surface Oncology, Inc. announced that they have entered into a definitive merger agreement, where, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.

Biosimilars 70

Biosimilars 70

Pharmaceutical Business Review

APRIL 15, 2024

Portage said that its board of directors decided to pause further enrolment in the ADPORT-601 clinical trial, which involves the study of PORT-6 and PORT-7, both adenosine antagonists. The post Immuno-oncology company Portage Biotech to evaluate strategic alternatives appeared first on Pharmaceutical Business review.

59

59

Pharma Mirror

OCTOBER 22, 2021

ADELAIDE, AUS, Oct 19, 2021 – (ACN Newswire) – Agilex Biolabs, the Australian regulated bioanalytical and toxicology laboratory facilities for clinical trials is presenting a new webinar entitled “Getting it right! Agilex Biolabs’ Director, Immunoassay, Kurt J. Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D,

Vaccines 52

Vaccines 52

Express Pharma

OCTOBER 17, 2023

Cellipoint Bioservices entered an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine. There has also been limited uptake of Provenge in the clinic due to its associated cost and initial unclear reimbursement status.

Vaccines 97

Vaccines Immunity Immunization 97

pharmaphorum

APRIL 8, 2022

billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. It was launched as Intron A by Schering-Plough (now Merck & Co) in the 1980s before being discontinued by the company in 2019 based on evaluation of its clinical activity and the emergence of alternative therapies.

Immunity 103

Immunity Immunization 103

pharmaphorum

JULY 23, 2021

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. The post Digital tools key to immuno-oncology’s future: report appeared first on.

52

52

Pharmaceutical Business Review

FEBRUARY 22, 2024

These regulatory milestones are based on data from the global, randomised, double-blind placebo-controlled Phase III INDIGO clinical trial of vorasidenib. It enrolled subjects with residual or recurrent grade two glioma carrying an IDH1/2 mutation, who had previously undergone surgery.

59

59

pharmaphorum

NOVEMBER 17, 2020

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications.

Drug Development 52

Drug Development 52

Pharmaceutical Technology

APRIL 10, 2023

Aviceda’s HALOS (high-affinity ligands of sigelcs) nanotechnology platform leverages glycobiology to modulate the innate immune system to develop advanced breakthrough therapeutics, focusing on immuno-oncology. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Immunity 103

Immunity Immunization Drug Development 103

pharmaphorum

JULY 8, 2021

GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. . billion acquisition of Tesaro, which added PARP inhibitor Zejula (niraparib) and a pipeline of other oncology candidates.

Compounding 104

Compounding 104

pharmaphorum

NOVEMBER 9, 2021

Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become exponentially more clinically targeted and sophisticated over the last decade. Yet how many other therapy areas have market leaders that don’t even have clinical approved indication in that indication?

Cerner 98

Cerner 98

Pharmafile

APRIL 13, 2023

Crescendo is a UK-based, clinical stage immuno-oncology company with an extensive proprietary pipeline of novel, targeted T cell enhancing Humabody® therapeutics. read more

40

40

pharmaphorum

MARCH 2, 2022

million upfront to kick off the collaboration, which will see Adagene’s SAFEbody technology applied to monoclonal and bispecific antibodies for a range of immuno-oncology applications. The French drugmaker is paying $17.5 Another $2.5 billion is in the offing in future milestone payments. That followed last year’s $3.2

Immunity 52

Immunity Immunization Drug Development 52

Pharmaceutical Technology

SEPTEMBER 8, 2022

On concluding the deal, the Good Therapeutics team intends to leverage its technology to design conditionally active therapies for other immuno-oncology targets and further in a new firm, Bonum Therapeutics.

Immunity 111

Immunity Immunization 111

Pharmaceutical Technology

JUNE 19, 2023

Coherus BioSciences has signed a definitive merger agreement to buy clinical-stage immuno-oncology (I-O) company Surface Oncology, in a deal valued at $65m. Coherus BioSciences will gain access to Surface Oncology’s two differentiated clinical stage assets, SRF388 and SFR114.

Biosimilars 52

Biosimilars Immunity Immunization 52

pharmaphorum

OCTOBER 17, 2022

Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed. Marie-Louise Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development.

Immunity 113

Immunity Immunization Drug Development 113

Pharmaceutical Technology

OCTOBER 14, 2022

It is currently being assessed in combination with Merck’s anti-PD-1 therapy, Keytruda, as an adjuvant treatment for high-risk melanoma patients in a Phase II clinical trial being conducted by Moderna.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

LifeProNow

APRIL 25, 2023

The trial met its primary endpoint of investigator-assessed progression-free survival (PFS), showing a statistically significant and clinically meaningful benefit versus placebo plus chemotherapy in patients treated with dostarlimab plus carboplatin-paclitaxel in the dMMR/MSI-H population. Jemperli was discovered by AnaptysBio, Inc.

Chemotherapy 130

Chemotherapy 130

pharmaphorum

OCTOBER 26, 2022

The stream of novel targets will leverage the proprietary discovery platforms of Normunity’s scientific founder Dr Lieping Chen, an immuno-oncologist who was one among other contributors within the field to identify PD-L1 (B7-H1). The emerging targets will be interrogated and validated together pre-clinically and clinically.

Immunity 52

Immunity Immunization 52

LifeProNow

MARCH 27, 2023

We will specifically allocate resources to grow our oncology and cardiology businesses in the U.S. Moving forward, we will focus our early research activities on core strategic areas: oncology, cardiovascular, neurology & rare diseases and immunology, where we believe we can make the biggest possible difference for the patients we serve.”

Bioethics 130

Bioethics Compounding Diabetes 130

European Pharmaceutical Review

FEBRUARY 7, 2023

MSD (Merck & Co) and Nectin Therapeutics have agreed to enter into a clinical trial collaboration, to investigate anti-PVR monoclonal antibody NTX1088 in combination with KEYTRUDA ® (pembrolizumab). The Phase I , open label clinical trial was initiated in November 2022.

Immunity 52

Immunity Immunization Labelling 52

Pharmafile

APRIL 18, 2023

Published date: 18/04/2023 Summary: NOUS-PEV demonstrated good safety and immunogenicity, and induced durable neoantigen-specific T cell responses that were detected for over 6 months and increased T cell infiltration in tumors demonstrating positive anti-tumor activity in solid tumors BASEL, Switzerland – 18th April 2023 - Nouscom, a clinical stage (..)

40

40

pharmaphorum

APRIL 20, 2022

per-share deal values CheckMate at around $250 million, and revolves around the toll-like receptor-9 (TKR9) agonist, which is in clinical testing in combination with other drugs for melanoma and non-melanoma skin cancers, as well as head and neck cancer. The post Regeneron seeks CheckMate in immuno-oncology play appeared first on.

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

MAY 4, 2023

Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. Clinical Lung Cancer. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. 2022; 24(2): 89 – 97.

Immunity 94

Immunity Immunization Chemotherapy 94

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. Rubius Therapeutics and Pathovax are in second and third positions, respectively.

Adverse Reactions 52

Adverse Reactions Mayo Clinic Immunity Immunization 52

PharmaShots

MAY 14, 2023

Shots: LaNova Medicines will receive an up front and near-term fees of ~$55M and is eligible to receive additional development and commercial milestones of ~$545M along with royalties on net sales globally AstraZeneca to get an exclusive license globally to research, develop, and commercialize LM-305, a pre-clinical stage ADC targeting G protein-coupled (..)

40

40

European Pharmaceutical Review

FEBRUARY 15, 2023

The results suggest “that neoadjuvant nivolumab was safe in long-term follow-up,” commented Patrick Forde, MBBCh, an Associate Professor of oncology and Director of the Thoracic Oncology Clinical Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Chemotherapy 91

Chemotherapy Immunity Immunization 91